Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification

Executive Summary

House hearing includes arguments that regulatory delays thwart the market’s response to shortage price signals, suggesting reforms could be included in user fee legislation along with the popular early warning requirement.


Related Content

Drug Shortage Scrutiny: GAO Plans Study Of FDA’s Expedited Applications
FDA Wants Compounding Authority Clarified, Congress Not So Sure It’s Necessary
Drug Shortages: Generic Industry’s Self Regulation Proposal Questioned At House Hearing
Shortage Notification May Have Legislative Momentum Again After BIO Questions Reimbursement Fix
“Comprehensive” Drug Shortage Mitigation Bill Under Development In House
Medicare Reimbursement Rate Targeted As Culprit For Drug Shortages
Drug Shortage Fixes Migrating Toward Economics
Drug Shortages: Can The Blame Game Help Find Solutions?
To Prevent Drug Shortages, Don't Look To Inspections, FDA Says
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts